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Background
Antibody-interferon-alpha (IFNa) fusion proteins repre-
sent a cancer therapeutic with properties of an antibody-
drug conjugate and an immunotherapy, having both direct
anti-tumor and immune-activating effects. We report the
anti-tumor activity of IGN004, an antibody-IFNa fusion
protein against a novel tumor-associated antigen expressed
by many solid and liquid tumors.
Methods
IGN004 was evaluated against a panel of human non-
small cell lung cancer (NSCLC), melanoma, multiple mye-
loma (MM), and AML cell lines. Binding was assessed
by flow cytometry and immunohistochemistry (IHC).
Anti-proliferative activity and T cell killing of tumor cells
by TALL-104 effector cells were assessed by MTS assay.
Human tumor xenografts were grown in immunodeficient
mice.
Results
IGN004 unfused antibody bound to the majority of tumor
cell lines and primary tumors assessed. Against tumor
antigen-positive cells in anti-proliferation experiments,
IGN004 demonstrated enhanced potency compared to
unfused IFNa while reduced potency was observed in cells
lacking antigen expression. IGN004 treatment upregulated
MHC class I, PD-L1, and OX-40L on tumor cells. In an in
vitro T cell killing assay using TALL-104 cells as effectors
and A549 NSCLC cells as targets, the addition of IGN004
led to enhanced effector cell killing of tumor (69.2% killing
without IGN004 vs. 100% killing with IGN004; p = 0.001).
Importantly, IGN004 demonstrated robust in vivo efficacy
against MM, NSCLC, AML, and melanoma xenografts,
including patient-derived xenografts (PDX). Against U266
MM xenografts, IGN004 fusion protein caused complete
regression of all tumors and achieved long-term survival
in 62.5% of mice. Efficacy was tested against a panel of 14
NSCLC PDX tumors and IGN004 had a response rate of
64%, including tumor regression in 29%. In an AML PDX
model, IGN004 treatment caused a reduction in AML
cells in the blood, spleen and bone marrow. Against a
PDX model of melanoma, IGN004 unfused antibody was
ineffective while IGN004 fusion protein inhibited tumor
growth.
Conclusions
IGN004 demonstrated robust anti-tumor activity against
both solid and liquid tumors. Targeting of IFNa to the
tumor cell surface via antibody resulted in enhanced
potency of growth inhibition. The relative IFNa bioactivity
is reduced against cells that do not express the target
antigen, which may result in a broader therapeutic index.
IGN004 demonstrated the ability to enhance the effector
T cell mediated killing of NSCLC cells in an in vitro assay.
Against human xenograft tumors, including PDX, IGN004
had robust in vivo anti-tumor efficacy. These results
support the further development of IGN004 as a targeted
cancer immunotherapy.
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